NCT00559650 - Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667 | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions

Congestive Heart Failure

Interventions

DRUG

Placebo

Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours

DRUG

Cinaciguat (BAY58-2667)

Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours

Trial Locations (72)

1000

Ljubljana

2600

Vác

3000

Celje

4032

Debrecen

4204

Golnik

8900

Zalaegerszeg

9000

Murska Sobota

10000

Zagreb

11000

Belgrade

12200

Berlin

12808

Prague

13419

Tallinn

15706

Santiago de Compostela

17007

Girona

17475

Greifswald

20010

Washington D.C.

20162

Milan

21000

Split

21204

Kamenitz

24128

Bergamo

27100

Pavia

28222

Majadahonda

32545

Bad Oeynhausen

34362

Haifa

40138

Bologna

44100

Ferrara

45014

Fairfield

50009

Kaunas

50924

Cologne

51014

Tartu

53105

Bonn

61231

Bad Nauheim

66424

Homburg

69120

Heidelberg

97080

Würzburg

99089

Erfurt

109263

Moscow

115093

Moscow

119435

Moscow

129010

Moscow

1311001

Safed

5262000

Ramat Gan

9112001

Jerusalem

92103-8765

San Diego

02114

Boston

45219-2316

Cincinnati

75216-7167

Dallas

B3H 3A7

Halifax

M5B 1W8

Toronto

G1V 4G5

Ste-Foy

625 00

Brno

656 91

Brno

500 05

Hradec Králové

301 00

Pilsen

128 08

Prague

06120

Halle

07740

Jena

H-1096

Budapest

06156

Perugia

08661

Vilnius

80-211

Gdansk

31-202

Krakow

70-111

Szczecin

50-981

Wroclaw

41-800

Zabrze

08036

Barcelona

08208

Sabadell

413 45

Gothenburg

751 85

Uppsala

S44 5BL

Chesterfield

EN5 3DJ

Barnet

HA1 3UJ

Harrow